Title : A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Pub. Date : 2015 Aug

PMID : 25947565






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CDK1/CDK2 inhibitors, such as dinaciclib, combined with anthracyclines, were synergistic in decreasing viability of TNBC cell lines. dinaciclib cyclin dependent kinase 2 Homo sapiens